Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 1999

View Archived Issues

Ganciclovir may reduce atherosclerosis in transplant patients

Combination immunotherapy kills melanoma in mice

Vical: Q2 1999 highlights

Viron Therapeutics awarded US patent for use of viral proteins as antiinflammatory agents

Pharmacia & Upjohn provides update on Q2 1999 progress

Bristol-Myers Squibb and ICAgen extend cardiovascular collaboration

Women First to market Fournier's estradiol patch in U.S.

Vaccination with HPV16 peptides in advanced cervical carcinoma

Liposome initiates clinical trial of Evacet in combination with Herceptin

Discovery Laboratories begins phase II tyloxapol trial in cystic fibrosis

MacroChem reports results of safety trials with Topiglan

Health Canada approves Integrilin for marketing

Vitravene approved in E.U. for CMV retinitis

Jenner Biotherapies receives patent protection for JBT-3002, a novel macrophage activator

GenVec gene therapy shows promising phase I results in patients with severe coronary artery disease

Dual 5-HT2/alpha1-adrenoceptor antagonists for treating cardiovascular disorders

Novel dual cephem-oxazolidinones described by Korean researchers

Novel cell adhesion inhibitors prepared by Rhone-Poulenc Rorer

Anti-H. pylori agents isolated from natural source by Takeda team

Hokuriku Seiyaku's STAT5 activators are useful for regulating platelet production

Teijin prepares factor Xa inhibitor series

ADIR discloses alkaloid derivatives with improved potency and solubility

FDA approves injectable, oral formulations of Wyeth-Ayerst's Protonix

Another pharmaceutical industry merger in the making: Cypros and RiboGene

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...